SMARCB1 and plasma cell myeloma: We found that our SMARCB1 deficient cell lines exhibited single digit nanomolar sensitivity to proteasome inhibition similar to that observed in the multiple myeloma cell line RPMI8226 (Figure 4—figure supplement 1c).